EUVIMEDScopri EUVIMED
Systematische ÜbersichtNetzwerk-Metaanalyse

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials

Jennifer Robblee iD, Sameh M Hakim iD, John M Reynolds iD, Teshamae S Monteith iD, Niushen Zhang, Meredith Barad iD

Headache: The Journal of Head and Face Pain · 2024-05 · 64 (5) · 547-572

DOI: 10.1111/head.14693 ↗

At a glance

Systematische Übersicht in Headache: The Journal of Head and Face Pain, published online on 2024-04-18. Written by Jennifer Robblee and 5 co-authors. Institution: Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Major MEDLINE topics: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Migraine Disorders, Randomized Controlled Trials as Topic. Cited 16 times so far (Crossref); 129 references. Funded by: American Academy of Pain Medicine (AAPM) Foundation, AAPM, American Association of Physicists in Medicine.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

To compare calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) versus nonspecific oral migraine preventives (NOEPs).

Background

Insurers mandate step therapy with NOEPs before approving CGRP mAbs.

Methods

Databases were searched for class I or II randomized controlled trials (RCTs) comparing CGRP mAbs or NOEPs versus placebo for migraine prevention in adults. The primary outcome measure was monthly migraine days (MMD) or moderate to severe headache days.

Results

Twelve RCTs for CGRP mAbs, 5 RCTs for topiramate, and 3 RCTs for divalproex were included in the meta‐analysis. There was high certainty that CGRP mAbs are more effective than placebo, with weighted mean difference (WMD; 95% confidence interval) of −1.64 (−1.99 to −1.28) MMD, which is compatible with small effect size (Cohen's d −0.25 [−0.34 to −0.16]). Certainty of evidence that topiramate or divalproex is more effective than placebo was very low and low, respectively (WMD −1.45 [−1.52 to −1.38] and −1.65 [−2.30 to −1.00], respectively; Cohen's d −1.25 [−2.47 to −0.03] and −0.48 [−0.67 to −0.29], respectively). Trial sequential analysis showed that information size was adequate and that CGRP mAbs had clear benefit versus placebo. Network meta‐analysis showed no statistically significant difference between CGRP mAbs and topiramate (WMD −0.19 [−0.56 to 0.17]) or divalproex (0.01 [−0.73 to 0.75]). No significant difference was seen between topiramate or divalproex (0.21 [−0.45 to 0.86]).

Conclusions

There is high certainty that CGRP mAbs are more effective than placebo, but the effect size is small. When feasible, CGRP mAbs may be prescribed as first‐line preventives; topiramate or divalproex could be as effective but are less well tolerated. The findings of this study support the recently published 2024 position of the American Headache Society on the use of CGRP mAbs as the first‐line treatment.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalCalcitonin Gene-Related PeptideMigraine DisordersRandomized Controlled Trials as TopicHumansAdministration, OralTopiramateValproic Acid

Author keywords

calcitonin gene–related peptide antagonistcalcitonin gene–related peptide monoclonal antibodiesinsurancemigrainepreventive treatment

Substances

Antibodies, MonoclonalCalcitonin Gene-Related PeptideTopiramateValproic Acid

Authors and institutions

  • Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
  • Department of Anesthesiology, Intensive Care, and Pain Management, Ain Shams University Faculty of Medicine, Cairo, Egypt.
  • The Louis Calder Memorial Library, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Headache, Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Neurology & Neurological Sciences, Stanford Health Care, Stanford, California, USA.
  • Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Health Care, Stanford, California, USA.

ORCID profiles: Jennifer Robblee, Sameh M Hakim, John M Reynolds, Teshamae S Monteith, Meredith Barad

Funding

  • American Academy of Pain Medicine (AAPM) Foundation
  • AAPM
  • American Association of Physicists in Medicine

Cite

APA

Robblee, J., Hakim, S. M., Reynolds, J. M., Monteith, T. S., Zhang, N., & Barad, M. (2024). Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials. Headache: The Journal of Head and Face Pain, 64(5), 547-572. https://doi.org/10.1111/head.14693

Vancouver

Robblee J, Hakim SM, Reynolds JM, Monteith TS, Zhang N, Barad M. Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials. Headache: The Journal of Head and Face Pain. 2024;64(5):547-572. doi:10.1111/head.14693

BibTeX
@article{Robblee2024,
  author = {Robblee, Jennifer and Hakim, Sameh M and Reynolds, John M and Monteith, Teshamae S and Zhang, Niushen and Barad, Meredith},
  title = {Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  volume = {64},
  number = {5},
  pages = {547--572},
  doi = {10.1111/head.14693}
}
Start for free →